Invitrogen

IDO Monoclonal Antibody (eyedio), PE, eBioscience™

FIGURE: 1 / 3

IDO Antibody (12-9477-42) in Flow

LEFT: Surface staining of normal human peripheral blood cells with Anti-Human CD3 PerCP-eFluor® 710 (Product # 46-0036-42), Anti-Human CD11c FITC (Product # 11-0116-42), Anti-Human CD85g (ILT7) APC (Product # 17-5179-42), and Anti-Human CD123 eFluor® 450 (Product # 48-1239-42) followed by staining with Fixable Viability Dye eFluor® 506 (Product # 65-0866-14). The cells were then intracellularly stained with Anti-Human IDO PE, using the Intracellular Fixation & Permeabilization Buffer Set (Product # 88-8824-00) and protocol. Single, viable ... View More

Product Image Gallery

Product Details

12-9477-42

Applications

Tested Dilution

Publications

Immunocytochemistry (ICC/IF)

View 1 publication 1 publication

Flow Cytometry (Flow)

5 µL (0.06 µg)/test

View 9 publications 9 publications

Miscellaneous PubMed (Misc)

View 1 publication 1 publication

Product Specifications

Species Reactivity

Human

Published species

Human

Host/Isotype

Mouse / IgG1, kappa

Recommended Isotype Control

Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), PE, eBioscience™

Class

Monoclonal

Type

Antibody

Clone

eyedio

Conjugate

PE PE PE

Excitation/Emission Max

565/576 nm View spectra

Form

Liquid

Concentration

5 µL/Test

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.2, with 0.2% BSA

Contains

0.09% sodium azide

Storage conditions

4° C, store in dark, DO NOT FREEZE!

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2572712

Product Specific Information

Description: This eyedio monoclonal antibody reacts with human indoleamine-2,3-dioxygenase (IDO, INDO, IDO1), an intracellular enzyme that catalyzes the degradation of tryptophan to kynurenines. IDO is expressed in a wide variety of tissues and cells, including macrophages, plasmacytoid dendritic cells, and several cell lines. IDO can be induced in many different cell types by IFN gamma or other inflammatory stimuli. Expression of IDO in antigen presenting cells and tumors is thought to mediate immune suppression through depletion of this essential amino acid and/or by the creation of tryptophan metabolites that causeapoptosis of T cells and induction of regulatory T cells.

Applications Reported: This eyedio antibody has been reported for use in intracellular staining followed by flow cytometric analysis.

Applications Tested: This eyedio antibody has been pre-titrated and tested by intracellular staining and flow cytometric analysis of normal human peripheral blood cells using the Intracellular Fixation & Permeabilization Buffer Set (Product # 88-8824-00) and protocol. Please refer to Best Protocols: Protocol A: Two step protocol for (cytoplasmic) intracellular proteins. This can be used at 5 µL (0.06 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

IDO1 is an intracellular heme-containing enzyme that catalyzes the oxidative cleavage of the indole ring of several important regulatory molecules like tryptophan, serotonin, and melatonin. By doing this, IDO1 initiates the production of biologically active metabolites, commonly referred to as kynurenines. IDO1 is widely expressed in a variety of human tissues as well as in macrophages and dendritic cells (DCs). In inflammation, interferons (IFNs) act on specific receptors to trigger IDO1 induction. The production of IFN-gamma and induction of IDO1 represent important antimicrobial mechanisms. Degradation and depletion of tryptophan by IDO1 inhibits the growth of viruses, bacteria and parasites. Furthermore, IDO1 plays a complex and crucial role in immunoregulation during infection, pregnancy, autoimmunity, transplantation, and neoplasia.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

How to use the Panel Builder

Watch the video to learn how to use the Invitrogen Flow Cytometry Panel Builder to build your next flow cytometry panel in 5 easy steps.

Product References

Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients.

Hematological oncology

Asano A,Ri M,Masaki A,Maeda Y,Tachita T,Hirade K,Marumo Y,Nakashima T,Hagiwara S,Kinoshita S,Suzuki T,Narita T,Kusumoto S,Komatsu H,Inagaki H,Iida S

12-9477-42 was used in Flow Cytometry to propose that aberrant Trp metabolism reduces anti-tumor immunity and the efficacy of Len therapy.

Tue Aug 01 00:00:00 EDT 2023

Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients.

Hematological oncology

Asano A,Ri M,Masaki A,Maeda Y,Tachita T,Hirade K,Marumo Y,Nakashima T,Hagiwara S,Kinoshita S,Suzuki T,Narita T,Kusumoto S,Komatsu H,Inagaki H,Iida S

12-9477-42 was used in Flow Cytometry to propose that aberrant Trp metabolism reduces anti-tumor immunity and the efficacy of Len therapy.

Tue Aug 01 00:00:00 EDT 2023

Mitochondrial interaction of fibrosis-protective 5-methoxy tryptophan enhances collagen uptake by macrophages.

Free radical biology & medicine

Maassen S,Warner H,Ioannidis M,Jansma J,Markus H,El Aidy S,Chiara MD,Chiara JL,Maierhofer L,Weavers H,van den Bogaart G